Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.

Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S.

Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1065-71.

PMID:
17674425
2.

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.

PMID:
20110009
4.

Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.

Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, Kurnik D, Lomnicky Y, Kokia E, Halkin H.

J Clin Pharmacol. 2011 Feb;51(2):173-80. doi: 10.1177/0091270010368281. Epub 2010 May 19.

PMID:
20484611
5.

Coronary heart disease outcomes in patients receiving antidiabetic agents.

McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.

Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25.

PMID:
17551989
6.

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].

PMID:
22118894
7.

Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.

Stockl KM, Le L, Zhang S, Harada AS.

Pharmacoepidemiol Drug Saf. 2009 Feb;18(2):166-74. doi: 10.1002/pds.1700.

PMID:
19109802
8.

Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.

Balkrishnan R, Arondekar BV, Camacho FT, Shenolikar RA, Horblyuk R, Anderson RT.

Clin Ther. 2007 Jun;29(6 Pt 1):1306-15.

PMID:
18036392
9.

Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.

Balkrishnan R, Arondekar BV, Camacho FT, Shenolikar RA, Horblyuk R, Anderson RT.

Clin Ther. 2007;29 Spec No:1306-15.

PMID:
18046930
10.

Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.

Winkelmayer WC, Setoguchi S, Levin R, Solomon DH.

Arch Intern Med. 2008 Nov 24;168(21):2368-75. doi: 10.1001/archinte.168.21.2368.

PMID:
19029503
11.

Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

Krentz A.

Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Review.

PMID:
19219860
12.

Thiazolidinediones and fractures in men and women.

Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM.

Arch Intern Med. 2009 Aug 10;169(15):1395-402. doi: 10.1001/archinternmed.2009.214.

PMID:
19667303
13.

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.

Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM.

BMJ. 2009 Aug 18;339:b2942. doi: 10.1136/bmj.b2942.

14.

Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.

Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11.

PMID:
24029780
15.

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA.

JAMA. 2010 Jul 28;304(4):411-8. doi: 10.1001/jama.2010.920. Epub 2010 Jun 28.

PMID:
20584880
16.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
17.

Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.

Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, Joseph G, Yu S.

Clin Drug Investig. 2013 Sep;33(9):621-31. doi: 10.1007/s40261-013-0106-9.

18.

Rosiglitazone and myocardial infarction in patients previously prescribed metformin.

Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM.

PLoS One. 2009 Jun 27;4(6):e6080. doi: 10.1371/journal.pone.0006080. Erratum in: PLoS One. 2010;5(7). doi: 10.1371/annotation/3330720e-5520-4211-91f3-d3b3d20e9804.

19.
20.

Supplemental Content

Support Center